Joseph Foss

Company: NeuroTherapia Inc

Job title: Chief Medical Officer

Seminars:

Using a Synthetic CB2-Targeting Compound to Target Neuroinflammation in the Brain, Mitigating Alzheimer’s Disease 2:00 pm

Keeping up with the evolving translational models of CB2-targeting compounds Understanding the pathways behind CB2-targeting to treat the neurological symptoms of AD through microglial-mediated neuroinflammation Preclinical and clinical research of a candidate compound, NTRX-07, that can readily penetrate the brain and modulate microglial activity via the CB2 receptor Exploring possible synergistic effects of NTRX-07 with…Read more

day: Day Two